Abstract

The decision of the United States (US) Supreme Court in Association for Molecular Pathology, et al. v Myriad Genetics, Inc., et al 569 U.S. 133 S.Ct. 2107 (2013) (the US Myriad case) was a landmark case on the patentability of biotechnological inventions. In particular the US Myriad case dealt with the issue of patentability of naturally occurring genes or nucleotide sequences, which have been isolated and characterised.